Drug intelligence / Profile preview

ALM-601

Development stage: Preclinical
Lead developer: Almac Discovery
Modality: Small Molecules

Overview

ALM-601 is a small molecule inhibitor of Ubiquitin Specific Peptidase 19 (USP19) currently under development by Almac Discovery. USP19 is a deubiquitinating enzyme (DUB) that plays a critical role in muscle protein degradation and metabolic homeostasis. By targeting USP19, ALM-601 aims to counteract muscle wasting and metabolic dysfunction associated with various conditions. The program is in the IND-enabling phase for the treatment of cardiometabolic disease, obesity, sarcopenic obesity, and cancer cachexia.

Targets

USP19 (Ubiquitin-specific peptidase 19)

Beyond the preview

Go deeper on ALM-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM-601.

Explore the full profile